Recent Updates
Recently added Catalysts
BDX Positive Sentiment Score: 70/100

BD to Present Next Installment of BD Innovates Series: Spotlight on Peripheral Vascular Disease BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next...

Key Takeaway: Becton, Dickinson and Company (BD) announced it will present the next installment of its BD Innovates series, focusing on solutions for Peripheral Vascular Disease. This event is scheduled for February 26, 2024, and will showcase BD's products and innovations within its Peripheral Intervention business unit. The presentation can be accessed via a live webcast, with a replay available after the event concludes. This initiative aligns with BD's 2025 Strategy aimed at advancing healthcare solutions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Highlighting innovative solutions for Peripheral Vascular Disease.
  • The BD Innovates series supports the company's long-term strategy.
  • Demonstrates BD's commitment to improving healthcare outcomes.

Full Press Release Details

FRANKLIN LAKES, N.J. , Feb. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series — which will highlight BD solutions that help clinicians treat Peripheral Vascular Disease — on Monday, February 26, 2024 , at 3:00 PM Eastern Time .
The BD Innovates series spotlights BD's innovation, products and pipeline in support of its BD 2025 Strategy, with this installment highlighting the Peripheral Vascular Disease platform within the BD Peripheral Intervention business unit.
The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion.
About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and on X (formerly known as Twitter) @BDandCo .
Contacts:
Media : Investors :
Troy Kirkpatrick Adam Reiffe
VP, Public Relations Sr. Director, Investor Relations
858.617.2361 201.847.6927
[email protected] [email protected]
SOURCE BD (Becton, Dickinson and Company)

21 %

Frequently Asked Questions

What is the BD Innovates series about?

The BD Innovates series showcases BD's innovations, products, and pipeline, focusing on medical technology.

When will the next BD Innovates presentation occur?

The next BD Innovates presentation is scheduled for February 26, 2024, at 3:00 PM ET.

How can I access the live BD presentation?

The live webcast can be accessed at BD's investor relations website, investors.bd.com.

What disease will be highlighted in the upcoming presentation?

The upcoming presentation will focus on solutions for treating Peripheral Vascular Disease.

Where can I find a replay of the presentation?

A replay of the presentation will be available on the BD investor relations website after the event.

Last updated: Feb 12, 2024